These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 8437224)

  • 1. Two mechanisms of soluble CD4 (sCD4)-mediated inhibition of human immunodeficiency virus type 1 (HIV-1) infectivity and their relation to primary HIV-1 isolates with reduced sensitivity to sCD4.
    Orloff SL; Kennedy MS; Belperron AA; Maddon PJ; McDougal JS
    J Virol; 1993 Mar; 67(3):1461-71. PubMed ID: 8437224
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Virions of primary human immunodeficiency virus type 1 isolates resistant to soluble CD4 (sCD4) neutralization differ in sCD4 binding and glycoprotein gp120 retention from sCD4-sensitive isolates.
    Moore JP; McKeating JA; Huang YX; Ashkenazi A; Ho DD
    J Virol; 1992 Jan; 66(1):235-43. PubMed ID: 1727487
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Direct measurement of soluble CD4 binding to human immunodeficiency virus type 1 virions: gp120 dissociation and its implications for virus-cell binding and fusion reactions and their neutralization by soluble CD4.
    Moore JP; McKeating JA; Norton WA; Sattentau QJ
    J Virol; 1991 Mar; 65(3):1133-40. PubMed ID: 1995942
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Envelope proteins from clinical isolates of human immunodeficiency virus type 1 that are refractory to neutralization by soluble CD4 possess high affinity for the CD4 receptor.
    Brighty DW; Rosenberg M; Chen IS; Ivey-Hoyle M
    Proc Natl Acad Sci U S A; 1991 Sep; 88(17):7802-5. PubMed ID: 1909031
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Conformational changes induced in the envelope glycoproteins of the human and simian immunodeficiency viruses by soluble receptor binding.
    Sattentau QJ; Moore JP; Vignaux F; Traincard F; Poignard P
    J Virol; 1993 Dec; 67(12):7383-93. PubMed ID: 7693970
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Equal levels of gp120 retention and neutralization resistance of phenotypically distinct primary human immunodeficiency virus type 1 variants upon soluble CD4 treatment.
    Groenink M; Moore JP; Broersen S; Schuitemaker H
    J Virol; 1995 Jan; 69(1):523-7. PubMed ID: 7983749
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Macrophage-tropic and T-cell line-adapted chimeric strains of human immunodeficiency virus type 1 differ in their susceptibilities to neutralization by soluble CD4 at different temperatures.
    O'Brien WA; Mao SH; Cao Y; Moore JP
    J Virol; 1994 Aug; 68(8):5264-9. PubMed ID: 8035523
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Factors underlying spontaneous inactivation and susceptibility to neutralization of human immunodeficiency virus.
    Layne SP; Merges MJ; Dembo M; Spouge JL; Conley SR; Moore JP; Raina JL; Renz H; Gelderblom HR; Nara PL
    Virology; 1992 Aug; 189(2):695-714. PubMed ID: 1386485
    [TBL] [Abstract][Full Text] [Related]  

  • 9. sCD4-17b bifunctional protein: extremely broad and potent neutralization of HIV-1 Env pseudotyped viruses from genetically diverse primary isolates.
    Lagenaur LA; Villarroel VA; Bundoc V; Dey B; Berger EA
    Retrovirology; 2010 Feb; 7():11. PubMed ID: 20158904
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of envelope V3 loop as the major determinant of CD4 neutralization sensitivity of HIV-1.
    Hwang SS; Boyle TJ; Lyerly HK; Cullen BR
    Science; 1992 Jul; 257(5069):535-7. PubMed ID: 1636088
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-HIV-1 activity of cellulose acetate phthalate: synergy with soluble CD4 and induction of "dead-end" gp41 six-helix bundles.
    Neurath AR; Strick N; Jiang S; Li YY; Debnath AK
    BMC Infect Dis; 2002 Apr; 2():6. PubMed ID: 11983022
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Blocking of human immunodeficiency virus infection depends on cell density and viral stock age.
    Layne SP; Merges MJ; Spouge JL; Dembo M; Nara PL
    J Virol; 1991 Jun; 65(6):3293-300. PubMed ID: 1674549
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Envelope conformational changes induced by human immunodeficiency virus type 1 attachment inhibitors prevent CD4 binding and downstream entry events.
    Ho HT; Fan L; Nowicka-Sans B; McAuliffe B; Li CB; Yamanaka G; Zhou N; Fang H; Dicker I; Dalterio R; Gong YF; Wang T; Yin Z; Ueda Y; Matiskella J; Kadow J; Clapham P; Robinson J; Colonno R; Lin PF
    J Virol; 2006 Apr; 80(8):4017-25. PubMed ID: 16571818
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of synergism/antagonism between HIV-1 antibody-positive human sera and soluble CD4 in blocking HIV-1 binding and infectivity.
    Kennedy MS; Orloff S; Ibegbu CC; Odell CD; Maddon PJ; McDougal JS
    AIDS Res Hum Retroviruses; 1991 Dec; 7(12):975-81. PubMed ID: 1687500
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neutralization of human immunodeficiency virus type 1 by sCD4-17b, a single-chain chimeric protein, based on sequential interaction of gp120 with CD4 and coreceptor.
    Dey B; Del Castillo CS; Berger EA
    J Virol; 2003 Mar; 77(5):2859-65. PubMed ID: 12584309
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Kinetics of soluble CD4 binding to cells expressing human immunodeficiency virus type 1 envelope glycoprotein.
    Dimitrov DS; Hillman K; Manischewitz J; Blumenthal R; Golding H
    J Virol; 1992 Jan; 66(1):132-8. PubMed ID: 1727475
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adaptation of two primary human immunodeficiency virus type 1 isolates to growth in transformed T cell lines correlates with alterations in the responses of their envelope glycoproteins to soluble CD4.
    Moore JP; Burkly LC; Connor RI; Cao Y; Tizard R; Ho DD; Fisher RA
    AIDS Res Hum Retroviruses; 1993 Jun; 9(6):529-39. PubMed ID: 8347397
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cryptic nature of a conserved, CD4-inducible V3 loop neutralization epitope in the native envelope glycoprotein oligomer of CCR5-restricted, but not CXCR4-using, primary human immunodeficiency virus type 1 strains.
    Lusso P; Earl PL; Sironi F; Santoro F; Ripamonti C; Scarlatti G; Longhi R; Berger EA; Burastero SE
    J Virol; 2005 Jun; 79(11):6957-68. PubMed ID: 15890935
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synergistic interaction between ligands binding to the CD4 binding site and V3 domain of human immunodeficiency virus type I gp120.
    McKeating JA; Cordell J; Dean CJ; Balfe P
    Virology; 1992 Dec; 191(2):732-42. PubMed ID: 1280382
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Soluble CD4-PE40 is cytotoxic for a transfected mammalian cell line stably expressing the envelope protein of human immunodeficiency virus (HIV-1), and cytotoxicity is variably inhibited by the sera of HIV-1-infected patients.
    Pitts TW; Bohanon MJ; Leach MF; McQuade TJ; Marschke CK; Merritt JA; Wierenga W; Nicholas JA
    AIDS Res Hum Retroviruses; 1991 Sep; 7(9):741-50. PubMed ID: 1742081
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.